Dimerix Limited awarded an Innovation Passport and the Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for DMX-200 being studied in a Phase 3 study in the serious kidney disease focal segmental glomerulosclerosis (FSGS). The ILAP is awarded to accelerate the development and access to promising medicines, such as DMX-200, and follows a review of clinical data that demonstrates patients are likely to benefit from the product. Entry with the Innovation Passport into the new ILAP provides a new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access. This means patients could benefit much sooner from this treatment and it will be accelerated through the approval process.